Disease Control with Prior Platinum-based Chemotherapy Is Prognostic for Survival in Patients with Metastatic Urothelial Cancer Treated with Atezolizumab in Real-world Practice

BACKGROUND: Atezolizumab, a programmed-death ligand-1 (PD-L1) inhibitor, is a novel treatment option for patients with metastatic urothelial cancer (mUC). Clinical prognostic factors, survival outcomes, and the safety of patients with mUC treated with atezolizumab, in a real-world setting, were inve...

Descripción completa

Detalles Bibliográficos
Autores principales: Mencinger, Marina, Mangaroski, Dusan, Bokal, Urska
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Sciendo 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8647786/
https://www.ncbi.nlm.nih.gov/pubmed/33939898
http://dx.doi.org/10.2478/raon-2021-0021

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8647786/
https://www.ncbi.nlm.nih.gov/pubmed/33939898
http://dx.doi.org/10.2478/raon-2021-0021

Ejemplares similares